fbpx
LaunchPad Company Presentations at OTS

Announcing Our Presenting Companies

Congratulations to our 4 presenting ophthalmology companies presenting at OTS 2019.  See below to learn more about their company!

Announcing Our Presenting Companies

LaunchPad is looking for companies that have a unique solution to a problem in ophthalmology.  If you are looking for $500k- $25M in funding and looking to amplify your investment capital strategy and want to present your company in front of Doctors, Investors, KOLs and Strategic Advisors, apply to LaunchPad today!

Cell Care Therapeutics

Cell Care Therapeutics, a preclinical stage biotechnology company, is pioneering the development of a cell-free biologic derived from the secretions of mesenchymal stem cells for the treatment of degenerative retinal diseases that lead to blindness. This novel product is a cell-free alternative to stem cell therapy that can be stored at room temperature and precisely reconstituted, dosed, and injected in ways that stem cells cannot. The company’s next-generation regenerative therapy will broaden the clinical applicability of regenerative medicine and expand patient access to these new treatment approaches.

IACTA Pharmaceuticals

IACTA Pharmaceuticals was established by former key Allergan executives to develop and commercialize innovative eyecare products. We’re dedicated to treating diseases, advancing technology and improving patient outcomes.  IACTA currently has two products in Phase 2 and two pre-clinical programs.

Lenstechs

Lentechs, LLC (“Lentechs”) is a privately-held, clinical stage ophthalmic medical device company focused on developing a portfolio of first-in-class suspended soft contact lenses. The Company’s flagship contact lens platform, APIOC®, is designed based on the natural structures of the eye and curvature of the cornea, utilizing proprietary front and back surfaces, and a patented unique ridge for suspension of the lens from the upper lid.

VisgenX

Visgenx, Inc. is developing therapeutics for “dry” Age- Related Macular Degeneration (AMD) a leading cause of blindness with currently no approved treatments. It affects more than 11 million in the US and > 196 million worldwide and represents a market potential of >$20 billion in the United States alone.  

Ophthalmology Technology Summit

June 28, 2019
Fashion Island Hotel, Newport Beach

Funded in part through a Cooperative Agreement with the U.S. Small Business Administration. Funding is not an endorsement of any product, opinion, or service. All programs are extended to the public on a nondiscriminatory basis. Reasonable accommodations for persons with disabilities will be made if requested at least two weeks in advance. Please contact Katrina Smith at (657) 278-3195 or via  [email protected]

Join Our Ecosystem

We’ll keep you updated on all things OCTANe.













OCTANe values your privacy. Please view our privacy policy here.

Contact

65 Enterprise
Aliso Viejo, CA 92656

949.330.6564

[email protected]

SITEMAP
SITEMAP